Avalyn Pharma Inc. AVLN
26.81 USD +1.21 (+4.73%)
At closeNov 3, 2026, 4:10 PM EST
26.81 0.00 0.00%
After hours · Nov 3, 4:10 PM ET
25.45 Day range 26.96
22.24 52-week range 40.17
- YTD
- -9.09%
- 1 year
- -9.09%
Analyst view
Price target (mean) 61.80 +130.5% upside
Now 26.81
- Target (low)
- 52.00
- Target (mean)
- 61.80
- Target (high)
- 80.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.75 | -0.79 – -0.71 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next quarter | -0.72 | -0.72 – -0.72 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | -2.69 | -2.69 – -2.69 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next year | -2.58 | -2.58 – -2.58 | -2.69 | +4.1% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Raymond James | Initiated | — | Outperform |
| Aug 13, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 26, 2026 | Evercore ISI Group | Initiated | — | Outperform |
| May 26, 2026 | Guggenheim | Initiated | — | Buy |
| May 26, 2026 | Morgan Stanley | Initiated | — | Overweight |